Working… Menu

Bevacizumab Alone Versus Dose-dense Temozolomide Followed by Bevacizumab for Recurrent Glioblastoma, Phase III (RE-GEND)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02761070
Recruitment Status : Recruiting
First Posted : May 4, 2016
Last Update Posted : September 1, 2020
Japan Clinical Oncology Group
Information provided by (Responsible Party):
Motoo Nagane, Kyorin University

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : July 10, 2024
Estimated Study Completion Date : July 10, 2024